Oncolix Inc

Oncolix — Investor Presentation (October 2017)

15 slides from Oncolix's investor presentation, Oct 11, 2017

  1. Slide 1: Breakthrough technology for women's cancers: Corporate Presentation

    AEPP Breakthrough technology for women’s cancers... Corporate Presentation October 2017 ©Oncolix 2017 @ncolix

  2. Slide 2: Safe Harbor

    Safe Harbor Certain of the statements and the projections set forth in this presentation constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may

  3. Slide 3: An Oncolix Investment

    An Oncolix Investment > Anew drug (Prolanta) with a novel mechanism of action (autophagy) > In human trials for treatment of ovarian cancer - drug shows evidence of efficacy and few side effects > Nobel Prize winner for Medicine awarded to Dr. Yoshinori Ohsumi for his pioneering work with autophagy

  4. Slide 4: Clinical Stage

    Clinical Stage Prolanta™: prolactin receptor antagonist Prolactin plays role in all gynecological cancers Dual mechanism of action Phase 1 ovarian cancer trial underway Asset Orphan Drug status for ovarian cancer Robust IP: 8 issued U.S. and foreign patents Upcoming — - Phase 1 monotherapy ovarian c

  5. Slide 5: Prolanta: First in Class Prolactin Antagonist

    Prolanta™: First in Class Prolactin Antagonist Recombinant protein analog of human prolactin that inhibits prolactin-induced oncogenic signaling Single amino acid mutation which prevents the activation of the prolactin receptor > Arginine replaces glycine at sequence 129 > Binds one receptor but not

  6. Slide 6: Prolactin Plays Significant Role in Women's Cancers

    Prolactin Plays Significant Role in Wo Cancers > Over-expressed Prolactin receptor found in many cancers Ovarian: 80% Breast: 90% Endometrial: 80% > Elevated prolactin levels are found in women’s cancers and contributes to pathogenesis of gynecologic malignances > Involved in cell proliferation sign

  7. Slide 7: $1 Billion Annual Opportunity: U.S. Ovarian Cancer Market

    $1 Billion Annual Opportunity: U.S. Ovarian Cancer Market Assumption: $40,000 per patient 22,440 Incidence 2017e, US Sensitive to Chemo 5,505 Patients , >6 mos. $220 Million 25% 188,117 Resistant to Chemo 5,506 Patients Prevalence, US us <6 mos. $220 Million Incidence 25% 22,240 Refractory or cannot

  8. Slide 8: Data Demonstrate Potential Efficacy in Ovarian Cancer

    Reduces size and s = = a B g a Source: Data Demonstrate Potential Efficacy in Oval Cancer number of tumors w o S x g Prolanta monotherapy ‘Tumor Weight ‘Tumor Nodutes Orthotopic ovarian cancer models, SKOV3 shown Prolanta with taxanes SKovs Lowest dose (100ug/day) G10) Tumor weight () MD Anderson Ca

  9. Slide 9: Prolanta shows evidence of synergistic efficacy in breast cancer models

    in breast cancer models Prolanta shows evidence of synergistic effi 501 2 control 5 400; * Herceptin s *G129R ; 5 30 —*G129R + Herceptin ee £ E 20 3 z 10 3 i 0 8 12 15 19 22 26 29 33 36 Days postinoculation Each value isa mean + SD of 6-8 mice/group ** P< 0.01 and*P < 0.05 versus control 7 P < 0.05

  10. Slide 10: Clinical Development Plan for Ovarian Cancer

    Clinical Development Plan for Ovarian Canc PhaselI Safety/Efficacy First 3 Patients Completed Monotherapy in 12 to 18 Platinum Resistant Subjects 99-day trial Phase Ila Safety/Efficacy Prolanta with Chemo Combination vs Chemo alone EMME in Recurrent Patients => Approval (Fast Track Breakthrough) 40

  11. Slide 11: Opportunities in Other Women's Cancers

    Opportunities in Other Women’s Ca Product Prolanta™™ Prolanta Prolanta Prolanta Protanta Indication ovarian cancer ovarian/ ‘comb Therapy uterine cancer Cervical Cancer Breast Cancer Mfg Optimisition _Pre-elinical Phase! Research | To be developed with Asian partner To be pursued with a pharmaceutic

  12. Slide 12: Capital Requirements

    Capital Requirements > Expanded sponsored research at MD Anderson for uterine cancer > Sponsored research at UC-SF for breast cancer $29.9* million capital raise to fund ovarian cancer through Phase 2b/3 trial Capital Requirements Through Phase 2b 2018 2019 2020 $5.2M $8.9M $15.8M *Assumes no acquis

  13. Slide 13: Experienced Management Team

    Experienced Management Team Michael Redman, CEO, BOD Formerly CEQ of Bone Medical, CEO and founder of Opexa Pharmaceuticals; VP, CorporateDevelopment, Aronex BhSimSceutests vb Business Bevckaomens Reproe Mharspeunes jee aioli laa abe Extensive Licensing and acquisition experience; Phase! through Itt

  14. Slide 14: Compelling Opportunity

    Compelling Opportunity & Clinical stage oncology asset, Prolanta™, is a first-in-class prolactin antagonist currently in Phase 1 for ovarian cancer FDA designated Prolanta™ as an Orphan Drug in ovarian cancer Serves an unmet dinical_need as patients treated with standard of care chemotherapy ‘eventu

  15. Slide 15: Thank You

    ro Thank You My Oncolix =

Oncolix — Investor Presentation (October 2017) on 6ix